Investor clashes with Akorn board after botched Fresenius tie-up
An investor has urged an Illinois federal court to disregard Akorn’s motion to dismiss their lawsuit, after a merger between the drugmaker and healthcare company Fresenius collapsed following revelations that the drugmaker misrepresented the state of its data.
To read more
Subscribe to Global Data Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Data Review experts.